Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy
November 29, 2016 8:31 AM ESTChardan Capital Markets reiterated a Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and raised the price target to $16.00 (from $15.00), as the company updates the US regulatory approval pathway for Galafold.
Analyst Gbola Amusa commented, "Yesterday, after market close, Amicus provided an update on... More
Leerink Partners Cuts Price Target on Amicus Therapeutics (FOLD) Following FDA Feedback
November 29, 2016 7:59 AM ESTLeerink Partners maintained an Outperform rating on Amicus Therapeutics (NASDAQ: FOLD), and cut the price target to $15.00 (from $17.00), following the company's announcement that the FDA feedback will lead to a new Galafold Ph.3 study slated to begin in 2017. Management will avoid disruptions to commercial launch in the EU and anticipates top-line data by 2019.... More
